John Tomaro

John Tomaro, Vice President, Clinical Operations, joined Bolt Biotherapeutics in 2020 with 18 years of experience in clinical operations, including first-in-human through Phase 3 clinical studies, primarily in oncology, immuno-oncology, and rare disease. Prior to joining Bolt, Mr. Tomaro led clinical operations at Sangamo Therapeutics, contributing to clinical development strategy across multiple programs. Before Sangamo, he held roles of increasing responsibility over a ten-year period at Celgene Corporation (now Bristol Myers Squibb), where he led multiple cross-functional teams in the execution of Phase 1-3 clinical trials. Mr. Tomaro previously worked in clinical operations at BioMarin Pharmaceutical and Quintiles Transnational (now IQVIA).

Mr. Tomaro received his master’s degree from the University of California at Santa Cruz and his bachelor’s degree from the University of North Carolina at Chapel Hill.